サンプル依頼リスト カート
  • English
  • Korean
表紙：網膜芽細胞腫の世界市場-2023年～2030年
市場調査レポート
商品コード
1352129

網膜芽細胞腫の世界市場-2023年～2030年

Global Retinoblastoma Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
網膜芽細胞腫の世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の網膜芽細胞腫市場は近年著しい成長を遂げています。この種の眼がんは5歳未満の小児に最も多いですが、まれに年長児や成人に発症することもあります。網膜芽細胞腫の治療は、眼内（眼球内）か眼外（眼球外）か、また腫瘍の大きさによって異なります。治療の選択肢としては、化学療法、凍結療法（凍結治療）、レーザー療法、放射線療法、手術などがあります。がんは組織、リンパ系、血液の3つの経路で転移します。

小児における網膜芽細胞腫の有病率の増加、意識の高まりと早期診断、より良い治療のための革新的な薬剤や治療法に対する需要の増加、臨床試験や研究活動の増加、診断方法の技術的進歩が、世界の網膜芽細胞腫市場を牽引すると予想される主な要因です。

ダイナミクス

革新的な薬剤や治療法に対する需要の増加が網膜芽細胞腫市場の成長を牽引

近年、小児における網膜芽細胞腫の有病率の増加により、患者の転帰を改善するための革新的な薬剤や治療法に対する需要が増加しています。個別化医療では、患者固有の遺伝子プロファイルや疾患特性に基づいて個々の患者に合わせた治療が行われ、網膜芽細胞腫を含む腫瘍学で脚光を浴びています。網膜芽細胞腫における革新的な薬剤の需要は、より正確で効果的な治療を提供し、より良い治療結果につながる可能性があるため、継続的に増加しています。

例えば、2023年2月14日、Alephoson Biopharmaceuticals Ltd.は、ペプチド-薬物複合体を開示しました。は、網膜芽細胞腫の治療に有用であると報告されているメルファランに共有結合した細胞透過性ペプチドからなるペプチド-薬物結合体を開示しました。

さらに、多くの臨床試験や研究活動が急速に進められており、より良い治療のための多くの革新的な発明につながっています。革新的な治療の選択肢には技術的進歩も含まれ、これらの進歩は疾患とそのメカニズムのより良い理解に役立ち、その結果、患者の転帰がより良く改善されます。それゆえ、多くの臨床試験や研究活動が革新的な治療法のために行われています。

同様に、2022年6月9日、Synthetic Biologics, Inc.は、遺伝子組換え腫瘍破壊性アデノウイルスであるVCN-01が、網膜芽細胞腫（RB）患者の治療薬としてFDAから希少疾病用医薬品の指定を受けたと発表しました。

意識の高まりと早期診断も網膜芽細胞腫市場の成長を後押し

網膜芽細胞腫に関する認知度の高まりは、早期診断とより良い治療という潜在的な利益をもたらします。網膜芽細胞腫の認知度は治療を強化する上で重要な役割を果たしており、早期に発見されれば完全に治癒する可能性があります。技術や技能の向上により、網膜芽細胞腫の子どもたちの生存率は向上していますが、認知度の低さは依然として懸念材料であるため、認知度の向上は多くの子どもたちの早期発見につながります。

例えば、2023年2月14日、汎米保健機構（PAHO）、聖ジュード小児研究病院、小児がん国際協会が開始した新しいキャンペーンは、ラテンアメリカとカリブ海諸国の両親、介護者、医療専門家に、小児と青少年に最も多いがんの最初の兆候である網膜芽細胞腫について注意を喚起し、タイムリーな診断と治療成績を向上させることを目的としています。

さらに、この腫瘍は世界ではあまり一般的ではなく、インドでの発生率は毎年出生1万人に1人程度で、片目または両目に影響を及ぼします。ラテンアメリカとカリブ海諸国では、毎年29,000人近くの子供と青年がこのタイプのがんと診断されています。このまれな小児眼がんは、英国では毎年約50人の乳幼児が罹患しています。したがって、認知度を高めることが早期診断と早期治療につながります。

例えば、2023年5月15日には、眼科病院であるサンカラ・ネトララヤが網膜芽細胞腫に関する啓発週間を開催します。白い怪物と呼ばれ、3歳未満の子供が罹患する眼のがんは、眼の中心または両眼の赤色反射または白色反射が非対称に変化するものです。

高い治療費が市場の成長を妨げる

標的療法は臨床試験で有望な結果を示していますが、開発・製造にはコストがかかります。これらの革新的な治療法の研究開発費は、臨床試験の実施費用と相まって、これらの薬剤の価格上昇につながる可能性があり、網膜芽細胞腫の治療を求める患者にとって購入しやすい価格に影響を与えます。

網膜芽細胞腫型がんの治療には、化学療法、放射線療法、手術などの長期にわたる治療が必要となる場合があります。このような長期にわたる治療は、患者やその家族にとって負担となる非常に高額な費用をもたらす可能性があります。また、高額な治療費も多くの医療提供者の負担となり、結果として網膜芽細胞腫市場の成長を阻害しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 革新的な薬剤や治療法に対する需要の増加
      • 意識の高まりと早期診断
    • 抑制要因
      • 高い治療費
    • 機会
      • 診断方法の技術的進歩
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 疾患タイプ別

  • 非遺伝性網膜芽細胞腫（散発性網膜芽細胞腫）
  • 遺伝性網膜芽細胞腫（家族性網膜芽細胞腫）

第8章 治療タイプ別

  • 手術療法
  • 放射線療法
  • 凍結療法
  • レーザー療法
  • 化学療法
  • その他

第9章 エンドユーザー別

  • 病院
  • 眼科クリニック
  • がん研究センター
  • 外来手術センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Pfizer Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Bristol Myers Squibb Company
  • Teva Pharmaceutical Pvt Ltd.
  • Merck and Co.
  • Novartis AG
  • GlaxoSmithKline PLC.
  • Johnson & Johnson
  • Baxter International, Inc.
  • AbbVie Inc.
  • Hikma Pharmaceuticals PLC

第13章 付録

目次
Product Code: PH6886

Overview

The global retinoblastoma market experiencing significant growth in recent years. This type of eye cancer is most common in children younger than age 5, but in rare cases, it can develop in older children or adults. Retinoblastoma treatment depends on whether it is intraocular (within the eye) or extraocular (outside the eye), and on the size of the tumor. Treatment options include chemotherapy, cryotherapy (freeze treatment), laser therapy, radiation, and surgery among others. Cancer can spread in the three ways such as tissue, the lymph system, and the blood.

The increasing prevalence of retinoblastoma in children, growing awareness and early diagnosis, increasing demand for innovative drugs and treatments for the better treatment, increasing clinical trials and research activities, and technological advancements in diagnostic methods are the major factors expected to drive the global retinoblastoma market.

Dynamics

Increasing Demand for Innovative Drugs and Treatments Drives the Growth of the Retinoblastoma Market

In recent years, the demand for innovative drugs and treatments are increasing for enhanced patient outcomes due to the increasing prevalence of retinoblastoma in children. Personalized medicine involves tailoring treatments to individual patients based on their unique genetic profile and disease characteristics gained prominence in oncology including retinoblastoma. The demand for innovative drugs in retinoblastoma is continuously increasing to provide more precise and effective therapies, potentially leading to better treatment outcomes.

For instance, on February 14, 2023, Alephoson Biopharmaceuticals Ltd. Disclosed peptide-drug conjugates comprising a cell-penetrating peptide covalently linked to melphalan that is reported to be useful for the treatment of retinoblastoma.

Moreover, many clinical trials and research activities are going on rapidly, leading to many innovative inventions for better treatment. The innovative treatment options also include technological advancements, these advancements help in a better understanding of the disease and its mechanisms resulting in better and enhanced patient outcomes. Hence, many clinical trials and research activities are even going on for innovative treatment options.

Similarly, on June 09, 2022, Synthetic Biologics, Inc. announced that VCN-01, a genetically modified oncolytic adenovirus received orphan drug designation by the FDA for the treatment of patients with retinoblastoma (RB).

Growing Awareness and Early Diagnosis Also Drive the Growth of the Retinoblastoma Market

Increasing awareness about retinoblastoma results in the potential benefits of early diagnosis and better treatment. Awareness of retinoblastoma plays a crucial role in enhanced treatment and it can be completely curable if detected early. With improved techniques and technologies, the survival of children with retinoblastoma has improved but low awareness is still a cause of concern, so increasing awareness leads to early detection in many children.

For instance, on 14 February 2023, a new campaign launched by the Pan American Health Organization (PAHO), St. Jude Children's Research Hospital, and Childhood Cancer International aims to alert parents, caregivers, and health professionals about the retinoblastoma in Latin America and the Caribbean about the first signs of the most common cancers in children and adolescents to improve timely diagnosis and treatment outcome.

Moreover, the tumor is not very common in the world, the incidence in India is about 1 in 10,000 live births each year, affecting either one or both eyes. In Latin America and the Caribbean, nearly 29,000 children and adolescents are diagnosed with this type of cancer each year. This rare childhood eye cancer affects around 50 babies and children in the UK every year. Hence, increasing awareness leads to early diagnosis and early treatment.

For instance, on May 15, 2023, Sankara Nethralaya, an eye hospital holds an awareness week on retinoblastoma. Called the white monster, cancer of the eye affects children under the age of three, it is the alteration of the red reflex or asymmetrical red reflex or white reflex in the center of an eye or both eyes.

High Treatment Costs Will Hamper the Growth of the Market

The targeted therapies are showing promising results in clinical trials, but they can be costly to develop and manufacture. The research and development costs for these innovative treatments, coupled with the expenses of conducting clinical trials, may lead to higher prices for these drugs, impacting their affordability for patients seeking retinoblastoma treatment.

The management of retinoblastoma type of cancer may involve prolonged treatment, including chemotherapy, radiation therapy, and surgeries. These long-term treatments can result in very high costs that can become a burden for patients and their families. Even the high treatment costs also become a burden for many healthcare providers, this resulting in hampering the growth of the retinoblastoma market.

Segment Analysis

The global retinoblastoma market is segmented based on disease type, treatment type, end-user and region.

The Non-Hereditary Retinoblastoma from Disease Type Segment Accounted for Approximately 35.7% of the Retinoblastoma Market Share

The non-hereditary retinoblastoma is also known as sporadic retinoblastoma. About 60% of children with retinoblastoma have non-hereditary retinoblastoma. Commonly, children are born with 2 normal copies of the RB1 gene. A mutation of both copies of the RB1 gene in a retinoblast causes a retinoblastoma tumor to form in the eye of the children. Children with non-hereditary retinoblastoma only develop a tumor in one eye known as unilateral retinoblastoma. They will not usually pass the RB1 mutation on to their future children.

Like all types of retinoblastoma, there is an easiest way to detect the abnormality in the eye of retinoblastoma children which is by a whitish spot in the pupil when the eye is exposed to direct light. It is often visible in pictures, because of the flash. If the spot called leukocoria is detected, then, the parents should be aware of the early diagnosis and better treatment. Since biopsies pose a threat to vision, scan tests such as MRIs and ultrasounds are typically used to look for tumors behind the eyes.

Geographical Penetration

North America Accounted for Approximately 41.2% of the Market Share, Owing to the Increasing Prevalence and Strong Presence of Major Players

Though the retinoblastoma is a rare disease, there is a high prevalence of this type of cancer in North America. The availability of comprehensive cancer treatments and advanced diagnostic capabilities allows for better disease monitoring, management, and treatment. According to the National Cancer Institute, there are 200 to 350 children in the United States who are estimated to be diagnosed annually with the disease.

North America, especially the United States is home to several major pharmaceutical companies, medical device manufacturers, and research institutions that are actively involved in the development and commercialization of retinoblastoma drugs and treatments. The region's established pharmaceutical and healthcare sectors attract significant investments and foster innovations in the retinoblastoma treatments.

Competitive Landscape

The major global players in the retinoblastoma market include Pfizer Inc., Bristol Myers Squibb Company, Teva Pharmaceutical Pvt Ltd., Merck and Co., Novartis AG, GlaxoSmithKline PLC., Johnson & Johnson, Baxter International, Inc., AbbVie Inc., and Hikma Pharmaceuticals PLC among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global retinoblastoma market. During the pandemic, mainly the healthcare systems faced the pressure to manage COVID-19 cases, leading to delayed regular healthcare services. Non-urgent medical appointments and elective surgeries are postponed or canceled to prioritize COVID-19 patients and reduce the risk of transmission. As a result, some children with retinoblastoma experienced delayed diagnosis and treatment, potentially affecting their treatment outcomes.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global retinoblastoma market. The conflict disrupts the retinoblastoma research-related activities and clinical trials. Many clinical trials and research activities related to retinoblastoma type of cancer were temporarily disrupted in the conflict regions, even led to the lack of many innovative treatment options globally.

Segmentation

By Disease Type

  • Non-hereditary retinoblastoma (sporadic retinoblastoma)
  • Hereditary retinoblastoma (familial retinoblastoma)

By Treatment Type

  • Surgery
  • Radiation Therapy
  • Cryotherapy
  • Laser Therapy
  • Chemotherapy
  • Others

By End-User

  • Hospitals
  • Ophthalmic Clinics
  • Cancer Research Centers
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On May 14, 2023, The Childhood Eye Cancer Trust (CHECT) released resources for healthcare professionals to help raise awareness of retinoblastoma. Ahead of World Retinoblastoma Awareness Week, held from 14-20 May, CHECT has created assets that professionals can use on social media to outline the signs and symptoms of retinoblastoma.
  • On Feb. 8, 2022, Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced that VCN Biosciences, S.L.'s VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. Food & Drug Administration (FDA). This announcement follows Synthetic Biologics' recent announcement that it had entered a definitive agreement to acquire VCN, which is subject to conditions that must be met prior to closing. VCN is developing a new oncolytic adenovirus (OV) platform designed to trigger tumor cell death and promote immune cell infiltration into tumors.

Why Purchase the Report?

  • To visualize the global retinoblastoma market segmentation based on disease type, treatment type, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of retinoblastoma market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global retinoblastoma market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Innovative Drugs and Treatments
      • 4.1.1.2. Rising Awareness and Early Diagnosis
    • 4.1.2. Restraints
      • 4.1.2.1. High Treatment Costs
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological Advancements in Diagnostic Methods
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Non-hereditary retinoblastoma (sporadic retinoblastoma) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Hereditary retinoblastoma (familial retinoblastoma)

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Surgery *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Radiation therapy
  • 8.4. Cryotherapy
  • 8.5. Laser therapy
  • 8.6. Chemotherapy
  • 8.7. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ophthalmic Clinics
  • 9.4. Cancer Research Centers
  • 9.5. Ambulatory Surgical Centers
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Pfizer Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Bristol Myers Squibb Company
  • 12.3. Teva Pharmaceutical Pvt Ltd.
  • 12.4. Merck and Co.
  • 12.5. Novartis AG
  • 12.6. GlaxoSmithKline PLC.
  • 12.7. Johnson & Johnson
  • 12.8. Baxter International, Inc.
  • 12.9. AbbVie Inc.
  • 12.10. Hikma Pharmaceuticals PLC

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us